# Efficacy and Safety of Baricitinib in Sjogren's Syndrome

> **NCT05016297** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 87 (actual)

## Conditions studied

- Sjogren's Syndrome

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT05016297
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-14
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016297, "Efficacy and Safety of Baricitinib in Sjogren's Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05016297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*